Tripartite motif protein 32 facilitates cell growth and migration via degradation of Abl-interactor 2

Cancer Research

Volumn 68, Issue 14, 2008, Pages 5572-5580

  Kano, Satoshi ^a   Miyajima, Naoto ^a   Fukuda, Satoshi ^a   Hatakeyama, Shigetsugu ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PEPTIDES AND PROTEINS; PROTEIN ABI2; PROTEIN ABL INTERACTOR 2; TRIPARTITE MOTIF PROTEIN 32; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ABI2 PROTEIN, HUMAN; ABI2 PROTEIN, MOUSE; HOMEODOMAIN PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TRANSCRIPTION FACTOR; TRIM32 PROTEIN, HUMAN; TRIM32 PROTEIN, MOUSE; UBIQUITIN PROTEIN LIGASE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL GROWTH; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL STRAIN 3T3; CELL TRANSFORMATION; CONTROLLED STUDY; HEAD AND NECK CARCINOMA; HEP 2 CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SQUAMOUS CELL CARCINOMA; UBIQUITINATION; ANIMAL; CELL MOTION; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HEAD AND NECK TUMOR; METABOLISM; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HOMEODOMAIN PROTEINS; HUMANS; MICE; NIH 3T3 CELLS; TRANSCRIPTION FACTORS; UBIQUITIN-PROTEIN LIGASES;

EID: 48649106832     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6231     Document Type: Article

References (38)

1. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998;67:425-79.
2. Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem 2001;70:503-33.
3. Huibregtse JM, Scheffner M, Beaudenon S, Howley PM. A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc Natl Acad Sci U S A 1995;92:2563-7.
4. Lorick KL, Jensen JP, Fang S, et al. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc Natl Acad Sci U S A 1999;96:11364-9.
5. Hatakeyama S, Yada M, Matsumoto M, Ishida N, Nakayama KI. U box proteins as a new family of ubiquitin-protein ligases. J Biol Chem 2001;276:33111-20.
6. Reymond A, Meroni G, Fantozzi A, et al. The tripartite motif family identifies cell compartments. EMBO J 2001;20:2140-51.
7. Urano T, Saito T, Tsukui T, et al. Efp targets 14-3-3σ for proteolysis and promotes breast tumour growth. Nature 2002;417:871-5.
8. Nakajima A, Maruyama S, Bohgaki M, et al. Ligand-dependent transcription of estrogen receptor α is mediated by the ubiquitin ligase EFP. Biochem Biophys Res Commun 2007;357:245-51.
9. Gack MU, Shin YC, Joo CH, et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 2007;446:916-20.
10. Quaderi NA, Schweiger S, Gaudenz K, et al. Opitz G/BBB syndrome, a defect of midline development, is due to mutations in a new RING finger gene on Xp22. Nat Genet 1997;17:285-91.
11. Consortium TIF; The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 1997;90:797-807.
12. Avela K, Lipsanen-Nyman M, Idanheimo N, et al. Gene encoding a new RING-B-box-Coiled-coil protein is mutated in mulibrey nanism. Nat Genet 2000;25:298-301.
13. Fridell RA, Harding LS, Bogerd HP, Cullen BR. Identification of a novel human zinc finger protein that specifically interacts with the activation domain of lentiviral Tat proteins. Virology 1995;209:347-57.
14. Slack FJ, Ruvkun G. A novel repeat domain that is often associated with RING finger and B-box motifs. Trends Biochem Sci 1998;23:474-5.
15. Frosk P, Weiler T, Nylen E, et al. Limb-girdle muscular dystrophy type 2H associated with mutation in TRIM32, a putative E3-ubiquitin-ligase gene. Am J Hum Genet 2002;70:663-72.
16. Chiang AP, Beck JS, Yen HJ, et al. Homozygosity mapping with SNP arrays identifies TRIM32, an E3 ubiquitin ligase, as a Bardet-Biedl syndrome gene (BBS11). Proc Natl Acad Sci U S A 2006;103:6287-92.
17. Yokota T, Mishra M, Akatsu H, et al. Brain site-specific gene expression analysis in Alzheimer's disease patients. Eur J Clin Invest 2006;36:820-30.
18. Albor A, El-Hizawi S, Horn EJ, et al. The interaction of Piasy with Trim32, an E3-ubiquitin ligase mutated in limb-girdle muscular dystrophy type 2H, promotes Piasy degradation and regulates UVB-induced keratinocyte apoptosis through NFnB. J Biol Chem 2006;281:25850-66.
19. Kudryashova E, Kudryashov D, Kramerova I, Spencer MJ. Trim32 is a ubiquitin ligase mutated in limb girdle muscular dystrophy type 2H that binds to skeletal muscle myosin and ubiquitinates actin. J Mol Biol 2005;354:413-24.
20. Horn EJ, Albor A, Liu Y, et al. RING protein Trim32 associated with skin carcinogenesis has anti-apoptotic and E3-ubiquitin ligase properties. Carcinogenesis 2004;25:157-67.
21. Albor A, Kulesz-Martin M. Novel initiation genes in squamous cell carcinomagenesis: a role for substrate-specific ubiquitylation in the control of cell survival. Mol Carcinog 2007;46:585-90.
22. Dai Z, Pendergast AM. Abi-2, a novel SH3-containing protein interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity. Genes Dev 1995;9:2569-82.
23. Lin TY, Huang CH, Chou WG, Juang JL. Abi enhances Abl-mediated CDC2 phosphorylation and inactivation. J Biomed Sci 2004;11:902-10.
24. Leng Y, Zhang J, Badour K, et al. Abelson-interactor-1 promotes WAVE2 membrane translocation and Abelson-mediated tyrosine phosphorylation required for WAVE2 activation. Proc Natl Acad Sci U S A 2005;102:1098-103.
25. Ichigotani Y, Yokozaki S, Fukuda Y, Hamaguchi M, Matsuda S. Forced expression of NESH suppresses motility and metastatic dissemination of malignant cells. Cancer Res 2002;62:2215-9.
26. Hirao N, Sato S, Gotoh T, et al. NESH (Abi-3) is present in the Abi/WAVE complex but does not promote c-Abl-mediated phosphorylation. FEBS Lett 2006;580:6464-70.
27. Dai Z, Kerzic P, Schroeder WG, McNiece IK. Deletion of the Src homology 3 domain and C-terminal proline-rich sequences in Bcr-Abl prevents Abl interactor 2 degradation and spontaneous cell migration and impairs leukemogenesis. J Biol Chem 2001;276:28954-60.
28. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12.
29. Voigt W. Sulforhodamine B assay and chemosensitivity. Methods Mol Med 2005;110:39-48.
30. Juang JL, Hoffmann FM. Drosophila abelson interacting protein (dAbi) is a positive regulator of abelson tyrosine kinase activity. Oncogene 1999;18:5138-47.
31. Ichigotani Y, Fujii K, Hamaguchi M, Matsuda S. In search of a function for the E3B1/Abi2/Argbp1/NESH family. Int J Mol Med 2002;9:591-5.
32. Meijer C, Mulder NH, de Vries EG. The role of detoxifying systems in resistance of tumor cells to cisplatin and adriamycin. Cancer Treat Rev 1990;17:389-407.
33. Kasahara K, Fujiwara Y, Nishio K, et al. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res 1991;51:3237-42.
34. Teicher BA, Holden SA, Kelley MJ, et al. Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res 1987;47:388-93.
35. Taniguchi K, Wada M, Kohno K, et al. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 1996;56:4124-9.
36. Kraker AJ, Moore CW. Elevated DNA polymerase β activity in a cis-diamminedichloroplatinum(II) resistant P388 murine leukemia cell line. Cancer Lett 1988;38:307-14.
37. Chu G, Chang E. Cisplatin-resistant cells express increased levels of a factor that recognizes damaged DNA. Proc Natl Acad Sci U S A 1990;87:3324-7.
38. Higuchi E, Oridate N, Furuta Y, et al. Differentially expressed genes associated with CIS-diamminedichloroplatinum (II) resistance in head and neck cancer using differential display and cDNA microarray. Head Neck 2003;25:187-93.